{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T20:47:52Z","timestamp":1757623672475,"version":"3.44.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007135","name":"University of Tennessee System","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007135","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Exploratory Research in Clinical and Social Pharmacy"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.rcsop.2023.100345","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T20:52:32Z","timestamp":1696539152000},"page":"100345","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Patient reported goals for medications for opioid use disorder: A theory of proximal goal attainment"],"prefix":"10.1016","volume":"12","author":[{"given":"Kenneth C.","family":"Hohmeier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Cernasev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Leibold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd M.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Schlesinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ileana","family":"Arce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wesley","family":"Geminn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Chisholm-Burns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Cochran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rcsop.2023.100345_bb0005","article-title":"Buprenorphine maintenance versus placebo or methadonemaintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"22","key":"10.1016\/j.rcsop.2023.100345_bb0010","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMp1402780","article-title":"Medication-assisted therapies\u2013tackling the opioid-overdoseepidemic","volume":"370","author":"Volkow","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.rcsop.2023.100345_bb0015","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1111\/add.14991","article-title":"Opioid agonist treatment and fatal overdose risk in a state-wide USpopulation receiving opioid use disorder services","volume":"115","author":"Krawczyk","year":"2020","journal-title":"Addiction."},{"author":"Centers for Disease Control and Prevention","key":"10.1016\/j.rcsop.2023.100345_bb0020"},{"issue":"3","key":"10.1016\/j.rcsop.2023.100345_bb0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.3821","article-title":"Use of medication for opioid use disorder among US adolescents and adults with need for opioid treatment, 2019","volume":"5","author":"Mauro","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.rcsop.2023.100345_bb0030","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1377\/hlthaff.2019.01085","article-title":"Impact of long-term buprenorphine treatment on adverse healthcare outcomes in Medicaid","volume":"39","author":"Samples","year":"2020","journal-title":"Health Aff (Millwood)"},{"issue":"2","key":"10.1016\/j.rcsop.2023.100345_bb0035","doi-asserted-by":"crossref","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative effectiveness of different treatment pathways foropioid use disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.rcsop.2023.100345_bb0040","doi-asserted-by":"crossref","first-page":"108028","DOI":"10.1016\/j.jsat.2020.108028","article-title":"Medication for opioid use disorder treatment and specialty outpatientsubstance use treatment outcomes: differences in retention and completion among opioid-related discharges in 2016","volume":"114","author":"Askari","year":"2020","journal-title":"J Subst Abus Treat"},{"issue":"2","key":"10.1016\/j.rcsop.2023.100345_bb0045","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/jrh.12375","article-title":"Rural clients\u2019 continuity into follow-up substance use disorder treatment: impacts of travel time, incentives, and alerts","volume":"36","author":"Garnick","year":"2020","journal-title":"J Rural Health"},{"issue":"10","key":"10.1016\/j.rcsop.2023.100345_bb0050","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1176\/appi.ps.201400140","article-title":"Stigma, discrimination, treatment effectiveness, andpolicy: public views about drug addiction and mental illness","volume":"65","author":"Barry","year":"2014","journal-title":"Psychiatr Serv"},{"issue":"5","key":"10.1016\/j.rcsop.2023.100345_bb0055","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1176\/appi.ps.201600056","article-title":"Social stigma towardpersons with prescription opioid use disorder: associations with public support for punitive and public healthoriented policies","volume":"68","author":"Kennedy-Hendricks","year":"2017","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.rcsop.2023.100345_bb0060","doi-asserted-by":"crossref","first-page":"108627","DOI":"10.1016\/j.drugalcdep.2021.108627","article-title":"The role of stigma in U.S. primary carephysicians\u2019 treatment of opioid use disorder","volume":"221","author":"Stone","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"10.1016\/j.rcsop.2023.100345_bb0065","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jamapediatrics.2018.2143","article-title":"Receipt of timely addiction treatment and association of earlymedication treatment with retention in care among youths with opioid use disorder","volume":"172","author":"Hadland","year":"2018","journal-title":"JAMA Pediatr"},{"issue":"2","key":"10.1016\/j.rcsop.2023.100345_bb0070","doi-asserted-by":"crossref","first-page":"e1920843","DOI":"10.1001\/jamanetworkopen.2019.20843","article-title":"Differences in availability and use of medications for opioid usedisorder in residential treatment settings in the United States","volume":"3","author":"Huhn","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.rcsop.2023.100345_bb0075","doi-asserted-by":"crossref","first-page":"160","DOI":"10.7326\/M19-3975","article-title":"Medication for opioid use disorder:a national survey of primary care physicians","volume":"173","author":"McGinty","year":"2020","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.rcsop.2023.100345_bb0080","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1377\/hlthaff.2018.05162","article-title":"Medication treatment for opioid use disorders in substanceuse treatment facilities","volume":"38","author":"Mojtabai","year":"2019","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"10.1016\/j.rcsop.2023.100345_bb0085","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/inm.12523","article-title":"Readiness and recovery: transferring between methadone and buprenorphine\/naloxone for the treatment of opioid use disorder","volume":"28","author":"Bishop","year":"2019","journal-title":"Int J Ment Health Nurs"},{"key":"10.1016\/j.rcsop.2023.100345_bb0090","doi-asserted-by":"crossref","first-page":"107968","DOI":"10.1016\/j.drugalcdep.2020.107968","article-title":"Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: a cross-sectional study","volume":"211","author":"Joudrey","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"10.1016\/j.rcsop.2023.100345_bb0095","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1176\/ajp.2007.164.5.797","article-title":"A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial","volume":"164","author":"Kakko","year":"2007","journal-title":"Am J Psychiatr"},{"issue":"4","key":"10.1016\/j.rcsop.2023.100345_bb0100","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jsat.2010.07.009","article-title":"The SUMMIT trial:: a field comparison of buprenorphine versus methadone maintenance treatment","volume":"39","author":"Pinto","year":"2010","journal-title":"J Subst Abus Treat"},{"issue":"1","key":"10.1016\/j.rcsop.2023.100345_bb0105","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jsat.2008.09.007","article-title":"Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence","volume":"37","author":"Ridge","year":"2009","journal-title":"J Subst Abus Treat"},{"issue":"25","key":"10.1016\/j.rcsop.2023.100345_bb0110","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.2174\/13816128113199990623","article-title":"Predictors of non-adherence to methadone maintenance treatment in opioid-dependent individuals: implications for clinicians","volume":"20","author":"Roux","year":"2014","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10.1016\/j.rcsop.2023.100345_bb0115","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/00952990802342899","article-title":"A meta-analysis of retention in methadone maintenance by dose and dosing strategy","volume":"35","author":"Bao","year":"2009","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1016\/j.rcsop.2023.100345_bb0120","article-title":"Patients\u2019 perspectives on coming off opioid agonist treatment: a qualitative study","volume":"16","author":"Nehlin","year":"2022","journal-title":"Subst Abuse: Res Treatment"},{"issue":"8","key":"10.1016\/j.rcsop.2023.100345_bb0125","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.19600","article-title":"Patient-reported goals of youths in Canada receiving medication-assisted treatment for opioid use disorder","volume":"4","author":"Chai","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.rcsop.2023.100345_bb0130","first-page":"113","article-title":"The inclusion of Patients\u2019 reported outcomes to inform treatment effectiveness measures in opioid use disorder. A systematic review patient related outcome measure","volume":"13","author":"Sanger","year":"2022"},{"issue":"12","key":"10.1016\/j.rcsop.2023.100345_bb0135","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025059","article-title":"Identifying patient-important outcomes in medication-assisted treatment for opioid use disorder patients: a systematic review protocol","volume":"8","author":"Sanger","year":"2018","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.rcsop.2023.100345_bb0140","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/0020764009354835","article-title":"Treatment goals in addiction healthcare: the perspectives of patients and clinicians","volume":"57","author":"Joosten","year":"2011","journal-title":"Int J Soc Psychiatry"},{"key":"10.1016\/j.rcsop.2023.100345_bb0145","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1590\/1516-4446-2019-0734","article-title":"The future of precision medicine in opioid use disorder: inclusion of patient-important outcomes in clinical trials","volume":"43","author":"Sanger","year":"2020","journal-title":"Brazilian J Psychiat"},{"issue":"1","key":"10.1016\/j.rcsop.2023.100345_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13722-021-00251-9","article-title":"Plausibility of patient-centered care in high-intensity methadone treatment: reflections of providers and patients","volume":"16","author":"Marshall","year":"2021","journal-title":"Addict Sci Clin Pract"},{"issue":"1","key":"10.1016\/j.rcsop.2023.100345_bb0155","first-page":"397","article-title":"Constructionism and the grounded theory method","volume":"1","author":"Charmaz","year":"2008","journal-title":"Handbook Construct Res"},{"issue":"3","key":"10.1016\/j.rcsop.2023.100345_bb0160","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1017\/S079096670001209X","article-title":"Sharing control: user involvement in general practice based methadone maintenance","volume":"28","author":"O\u2019Reilly","year":"2011","journal-title":"Ir J Psychol Med"},{"issue":"1","key":"10.1016\/j.rcsop.2023.100345_bb0165","first-page":"1","article-title":"Building healthcare provider relationships for patient-centered care: a qualitative study of the experiences of people receiving injectable opioid agonist treatment","volume":"15","author":"Marchand","year":"2020","journal-title":"Subst Abuse Treat Prev Pol"},{"key":"10.1016\/j.rcsop.2023.100345_bb0170","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2147\/NDT.S129480","article-title":"The impact of comorbid psychiatric disorders on methadone maintenance treatment in opioid use disorder: a prospective cohort study","volume":"13","author":"Rosic","year":"2017","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"10.1016\/j.rcsop.2023.100345_bb0175","first-page":"1","article-title":"The exploration of factors related to treatment retention in narcotics anonymous members: a qualitative study","volume":"14","author":"Jalali","year":"2019","journal-title":"Subst Abuse Treatment Prevent Pol"},{"issue":"2","key":"10.1016\/j.rcsop.2023.100345_bb0180","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/1049731520972798","article-title":"Performance-based practice: clinical dashboards for addiction treatment retention","volume":"31","author":"Patterson Silver Wolf","year":"2021","journal-title":"Res Soc Work Pract"},{"year":"2022","series-title":"Inside and outside the zone of proximal development: An ecofunctional reading of Vygotsky","author":"Del Rio","key":"10.1016\/j.rcsop.2023.100345_bb0185"},{"key":"10.1016\/j.rcsop.2023.100345_bb0190","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1007\/978-3-030-39903-0_70","article-title":"Transtheoretical model of behavior change","volume":"20","author":"Prochaska","year":"2020","journal-title":"Encyclop Behav Med"},{"issue":"53\u201392","key":"10.1016\/j.rcsop.2023.100345_bb0195","first-page":"2","article-title":"Action phases and mind-sets","volume":"2","author":"Gollwitzer","year":"1990","journal-title":"Handbook of motivation and cognition: Foundations of social behavior"},{"key":"10.1016\/j.rcsop.2023.100345_bb0215","doi-asserted-by":"crossref","first-page":"108402","DOI":"10.1016\/j.jsat.2021.108402","article-title":"Family involvement in treatment and recovery for substance use disorders among transition-age youth: research bedrocks and opportunities","volume":"129","author":"Hogue","year":"2021","journal-title":"J Subst Abus Treat"},{"key":"10.1016\/j.rcsop.2023.100345_bb0220","doi-asserted-by":"crossref","first-page":"108649","DOI":"10.1016\/j.drugalcdep.2021.108649","article-title":"Familial perceptions of appropriate treatment types and goals for a family member who has opioid use disorder","volume":"221","author":"Nayak","year":"2021","journal-title":"Drug Alcohol Depend"}],"container-title":["Exploratory Research in Clinical and Social Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667276623001269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667276623001269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T08:31:37Z","timestamp":1757406697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667276623001269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":41,"alternative-id":["S2667276623001269"],"URL":"https:\/\/doi.org\/10.1016\/j.rcsop.2023.100345","relation":{},"ISSN":["2667-2766"],"issn-type":[{"type":"print","value":"2667-2766"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient reported goals for medications for opioid use disorder: A theory of proximal goal attainment","name":"articletitle","label":"Article Title"},{"value":"Exploratory Research in Clinical and Social Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rcsop.2023.100345","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100345"}}